Minimally Invasive Ridge Splitting Versus the Conventional Open Flap Technique

NCT ID: NCT06329362

Last Updated: 2024-03-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-07-31

Study Completion Date

2025-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to compare implant stability, and crestal bone loss, when using minimal invasive ridge splitting versus convenient open flap technique. The main question is Does Minimal Invasive Implant ridge splitting ("transmucosal" without flap) influence the implant stability and crystal bone loss, when compared with the conventional open flap techniques? Researchers will compare Group A: Minimal Invasive Implant ridge splitting and Group B: Triangular flap technique is used to see if there is significant difference between the two groups when measuring implant stability, and crestal bone density.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Diagnostic stage:

Explanation of the operative procedure and obtaining the participants consent. Comprehensive clinical examination and understanding of participants chief complains and needs will be carried out.

CBCT acquisition:

Cone Beam Computed Tomography (CBCT) scans for the participants will be Taken preoperatively to determine the following:

1. Bone density (D1 \& D4 for exclusion, while D2 \& D3 shall be included)
2. To confirm the ridge mapping indicating alveolar ridge class IV. (Where height is adequate \> 10mm, while width is "3-4 mm").

Planning the surgical procedure:

All planned surgical procedure will be carried out by main candidate under supervision.

Implant are planned to be placed (2 implants are placed in each segment "30-40 mm")

Surgical procedure:

Scrubbing and draping of the participants will be carried out in a standard fashion.

Local anesthesia (lidocaine 2%o,1/100000 adrenaline) Group A: Minimal Invasive Implant ridge splitting. A horizontal incision is made using fine end bur with high-speed hand piece deep from the edge of the ridge, passing down the cortical plate to the depth of the spongy bone, without mucoperiosteal elevation.

Using specially designed implant like bone expanders (Champions implants GmbH) to widen ridge with sequential application (which are 2.4, 2.8, 3.0, 3.3,3.8,4.3, and 5.3 mm in Diameter).

With each step the investigators shall carefully check the bone integrity and depth using calibrated probe.

By reaching the desired depth and width (till size 3.3 condensers and place 3.5 x 8 mm implants as a standard, using torque gage adjusted at 30-40 Newton's, that's to avoid pressure that might lead to initial resorption.

Closure of the incision line using interrupted suturing.

Group B: Triangular flap technique is used. With the horizontal component on the ridge and the vertical component posteriorly to avoid injury to the mental nerve, allowed by mucoperiosteal elevation to expose the target area.

2 vertical cuts on both ends to facilitate the ridge expansion, without the risk of crack or fracture of the buccal segment using conventional chisels till reaching the desired width that would accommodate the same implant diameter as for group A.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alveolar Bone Loss

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Minimal Invasive Implant ridge splitting

Using minimally invasive implant placement in atrophied ridge without mucoperiosteal flap, and specially designed implant shaped expanders.

Group Type ACTIVE_COMPARATOR

Minimally invasive implantation

Intervention Type PROCEDURE

Specially designed ridge splitting instrumentation by Champions Implant GmbH which is implant shaped expanders.

conventional open flap ridge splitting implantation.

Using the conventional open flap technique with mucoperiosteal elevation to expose the ridge with the use of conventional bone expanders and chisels.

Group Type ACTIVE_COMPARATOR

Open flap procedure for ridge expansion.

Intervention Type PROCEDURE

Mucoperiosteal elevation and ridge splitting using conventional ridge expanders.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Minimally invasive implantation

Specially designed ridge splitting instrumentation by Champions Implant GmbH which is implant shaped expanders.

Intervention Type PROCEDURE

Open flap procedure for ridge expansion.

Mucoperiosteal elevation and ridge splitting using conventional ridge expanders.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Champions Implant GmbH Ridge splitting.

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with atrophic posterior mandibular ridge with edentulous area 30-40 mm, minimum width 3-4 mm, and adequate height indicated for implant placement \>9 mm.
2. Patient with Bone density D2 and D3.
3. Good general systemic condition.
4. Committed patient to attend follow up appointment.

Exclusion Criteria

1. Patients with systemic diseases that may affect the healing process of hard or soft tissues (e.g., uncontrolled diabetes mellitus).
2. Patient on medication that could hinder the normal healing process (e.g., steroids, immunosuppressant)
3. Patients with intra-bony lesions or infections.
4. Patient with bad habits (e.g. alcohol or Substance abuse).
5. Patient who received head and neck radiotherapy or chemotherapy in the last 10 years.
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Royal College of Surgeons of Edinburgh

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Bassem Emad AbdElMoneim

Oral and Maxillofacial Surgeon

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Emad Deif, Prof.

Role: STUDY_CHAIR

Head of Oral and Maxillofacial Surgery Department - Faculty of Dentistry Cairo University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Faculty of Dentistry Cairo University

Cairo, , Egypt

Site Status RECRUITING

Future Dental Academy GmbH

Flonheim, Rhineland-Palatinate, Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Bassem Hussein, MDs

Role: CONTACT

+201001113474

Emad Deif, Prof

Role: CONTACT

+201222331938

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Bassem Emad, MDs

Role: primary

+201001113474

Emad Deif, Prof

Role: backup

+201222331938

Armin Nadjet, A.Prof

Role: primary

+4915115253692

Rainer Zoppke

Role: backup

+491778339601

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2-7-23

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.